PACB earnings

MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). The call will be webcast and may be accessed on PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, May 7, 2026, at 4:30 p.m. ET (1:30 p.m. PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures a

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pull-through per system~$242,000~$240,000~$233,000~$252,000Ending cash, cash equivalents, and investments(in millions)$279.5$389.9   Gross margin, operating expenses, net inco

MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advan

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. "We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications," said Christian Henry, President and CEO of PacBio. "In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Look

MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results:  Q3 2025Q3 2024Revenue$38.4 million$40.0 millionInstrument revenue$11.3 million$16.8 millionConsumable revenue$21.3 million$18.5 millionService and other revenue$5.8 million$4.7 millionRevio™ systems1322Vega™ systems32—Annualized Revio pull-through per system~$236,000~$255,000Cash, cash equivalents, and investments$298.7 million$471.1 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corr

MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBi

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspo

MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the

Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year decline of 33% and 23%, respectively. "Though challenging, 2024 was a productive year for PacBio as we launched groundbreaking products, strengthened our balance sheet, and made significant pr

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 million in the prior-year period.Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the third quarter of 2024 included 22 Revio™ sequencing systems.Consumables revenue of $18.5 million compared with $16.9 million in the prior-year period.Service and other revenue of $4.7 million compared with $4.1 million in the prior-year period. Gross profit, operating expenses, net loss, and net loss per share are reported on

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio

MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 million in the prior-year period.Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. Instrument revenue in the second quarter of 2024 included 24 Revio™ sequencing systems.Consumables revenue of $17.0 million compared with $13.7 million in the prior-year period.Service and other revenue of $4.3 million compared with $3.9 million in the prior-year period. Gross profit for the second quarter of 2024 was $5.9 million, which included $4.6 mil

MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Wednesday, August 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q

MENLO PARK, Calif., May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2024. First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period.Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument revenue in the first quarter of 2024 included 28 RevioTM sequencing systems.Consumables revenue of $16.0 million compared with $14.0 million in the prior-year period.Service and other revenue of $3.8 million compared with $4.2 million in th

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif., April 16, 2024  /PRNewswire/ – PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period.Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period.Consumables revenue of $16.0 million compared with $14.

MENLO PARK, Calif., Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period.Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period.Consumables revenue of $18.9 million compared with $16.7 million in the prior-year period.Service and other revenue of $4.4 million compared with $4.6 million in the prior-year period.Shipped 44 RevioTM sequencing s

MENLO PARK, Calif., Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Thursday, February 15, 2024, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please

Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity MENLO PARK, Calif., Jan. 8, 2024 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million representing year-over-year growth of 113% and 56%, respectively.

MENLO PARK, Calif., Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Monday, October 30, 2023, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please dial i

MENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2023. Second quarter results Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior year-period.Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the prior-year period.Instrument revenue of $29.9 million compared with $15.6 million in the prior-year period.Consumables revenue of $13.7 million compared with $14

PacBio will Combine Apton's Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into an agreement to acquire Apton Biosystems, Inc (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell.

MENLO PARK, Calif., July 19, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Wednesday, August 2, 2023, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please dia

MENLO PARK, Calif., May 2, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2023. First quarter results Revenue of $38.9 million, a 17% increase compared with $33.2 million in the prior year period.Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe systems.Instrument revenue of $20.7 million compared with $15.6 million in the prior-year period. Consumables revenue of $14.0 million compared with $12.7 million in the prior-year period. Service and other revenue of $4.2 million

MENLO PARK, Calif., April 18, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Tuesday, May 2, 2023 at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-6011 If using the dial-in option, please dial into th

MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Thursday, February 16, 2023 at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 866-652-5200International: 412-317-6060 If using the dial-in option

PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history. On October 25, 2022, PacBio announced two new sequencing platforms, Revio and Onso. Revio is a revolutionary new long-rea

MENLO PARK, Calif., Nov. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results Revenue of $32.3 million, a 7% decrease compared with $34.9 million in the prior year period.Instrument revenue of $11.4 million, compared with $15.9 million in the prior year period. Consumables revenue of $16.1 million compared with $14.6 million in the prior year period. Service and other revenue of $4.8 million, compared with $4.4 million in the prior year period.Delivered 34 Sequel IIe systems, compared wit

Withdraws Guidance with New Product Announcement MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time. PacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time. The event will feature presentations by members of PacBio's executive team and include Q&A sessions. Both events will be webcast live and may be accessed at PacBio's website at:  https://inve

MENLO PARK, Calif., Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2022. Second quarter results Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Delivered 36 Sequel II/IIe systems, compared with 38 Sequel II/IIe systems in the prior year period.Installed base of 460 Sequel II/IIe systems as of June 30, 2022, compared with 282 as of June 30, 2021.Instrument revenue of $15.6 million, compared with $14.3 million in the prior year period. Consumables revenue of $14.6 mi

MENLO PARK, Calif., July 18, 2022 /PRNewswire/ -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2022 financial results on Wednesday, August 3, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Wednesday, August 3, 2022 Time: 5:00pm ET (2:00pm PT) Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 866-652-5200 International: 412-317-6060 Replay: https://investor.pacificbiosciences.com If

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.Delivered a record 50 Sequel II/IIe systems during the quarter compared to 41 Sequel II/IIe systems placed in the prior year quarter.Installed base of 424 Sequel II/IIe systems as of March 31, 2022, compared with 244 as of March 31, 2021.Instrument revenue of $15.6 million, compared with $14.9 million in the prior-year period.Consumables revenue of $12.7 million compared with $10.4 million in the prior-year period.Service and othe

MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time. The call will be webcast live and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/. Date: Wednesday, May 4, 2022 Time: 5:00pm ET (2:00pm PT) Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 866-652-5200 International: 412-317-6060 Replay: https://investor.pacificbiosciences.com If using the dial-in option, please dial into the call five to ten minutes prior to start time using the approp

MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release Achieved record fourth quarter revenues of $36.0 million reflecting growth of 33% compared to the prior year period and grew the Sequel II/IIe installed base by 84% to 374 as of December 31, 2021.Launched the HiFiViral SARS-CoV-2 Kit – a fully kitted end-to-end solution for COVID-19 surveillance that public health laboratories can use to identify new SARS-CoV-2 variants and detect all circulating variants within a population.Developed significant enhancements to the Sequel II/IIe platf

MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time. The call will be webcast live and may be accessed at Pacific Biosciences' website at: https://investor.pacificbiosciences.com/. Date: Tuesday, February 15, 2022 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 3580907 Replay: https://investor.pacificbiosciences.com About PacBio Pacific Biosciences of California, Inc. (NASDAQ:PAC

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021. The Company's full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available. Business Updates: Expect preliminary fourth quarter revenue of approximately $36.0 million, representing an increase of approximately 33% compared with $27.1 million for the fourth quarter of 2020. As a result, preliminary annual 2021 revenue is expected to be $130.5 million, representing a

MENLO PARK, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended September 30, 2021. Record revenue reflects 6th straight quarter of sequential growth Revenue of $34.9 million, an 83% increase compared with $19.1 million in the prior year period.Placed 44 Sequel II/IIe systems during the quarter compared to 20 Sequel II systems placed in the prior year quarter and 38 Sequel II/IIe systems placed in the second quarter of 2021.Installed base of 326 Sequel II/IIe systems as of September 30, 2021, compared with 168 as of September 30, 2020.Instrument revenue of $15.9 million, compared with $7.7 million in the prior year period

MENLO PARK, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its third quarter 2021 financial results on Tuesday, November 2, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences' website at: https://investor.pacificbiosciences.com/. Date: Tuesday, November 2, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 5129207 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ:PACB

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue reflects continued quarter-over-quarter growth Revenue for the second quarter of 2021 was $30.6 million, representing an 79% increase compared with $17.1 million for the second quarter of 2020. The Company placed 38 Sequel II/IIe systems during the second quarter of 2021 compared to 23 Sequel II systems placed in the second quarter of 2020 and 41 Sequel II/IIe systems placed during the first quarter of 2021, bringing the total installed base of Sequel II/IIe systems to 282 as of Jun

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) ("Pacific Biosciences" or "PacBio"), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. ("Circulomics"), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows. Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type. These products are commonly used for long read applications across a diverse set of markets including, human biomedical research, plant and animal sc

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical marketsBrings together Omniome's high accuracy short-read sequencing platform, with PacBio's market leading, high accuracy long-read solutionsTransaction supported by concurrent $300 million PIPE financing from premier life science investors MENLO PARK, Calif. and SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) ("Pacific Biosciences" or "PacBio"), a leading provider of high-quality, long-read sequencing platforms, announced today that it has signed a definitive merger agreement under which it will acquire Omniom

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences' website at: https://investor.pacificbiosciences.com/. Date: Tuesday, August 3, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-free: 888.366.7247 International: 707.287.9330 Conference ID: 6914707 Replay: https://investor.pacificbiosciences.com About Pacific Biosciences Pacific Biosciences of California, Inc. (NASDAQ:PACB) i